Infection recurrence following minimally invasive treatment in patients with infectious pancreatic necrosis

Table 3 Clinical characteristics of patients who underwent minimally invasive treatment for infectious pancreatic necrosis

	Patients without recurrent infection, n = 156	Patients with recurrent infection, n = 13	P value
Time onset of IPN in d	53 ± 1	55 ± 5	0.796
Cause of IPN, n (%)
Biliary	92 (58.97)	6 (46.15)	0.543
Alcohol	23 (14.74)	3 (23.08)	0.136
Idiopathic	5 (3.21)	1 (7.69)	0.386
Hypertriglyceridemia	36 (23.08)	3 (23.08)	1.000
BISAP score	3.53 ± 0.05	3.62 ± 0.14	0.632
APACHE II score	9.56 ± 0.18	8.92 ± 0.40	0.328
Impaired mental status, n (%)	21 (13.46)	2 (15.38)	0.302
SIRS, n (%)	146 (93.59)	12 (92.31)	0.395
Pre-operative blood test
WBC as 109/L	14.59 ± 0.281	15.32 ± 0.601	0.466
BUN in mmol/L	10.45 ± 0.501	9.09 ± 0.971	0.440
Creatinine in µmol/L	156.86 ± 9.091	115.61 ± 10.601	0.195
CRP in mg/L	66.47 ± 5.631	42.66 ± 10.441	0.230
IL-6 in pg/mL	62.25 ± 7.791	53.05 ± 8.451	0.735
Procalcitonin in ng/mL	2.44 ± 0.191	2.29 ± 0.551	0.823
Minimally invasive treatment			0.157
Sole treatment with PCD/VARD/LATOD, n (%)	86 (55.13)	4 (30.77)
Combined treatment, n (%)	70 (44.87)	9 (69.23)
Post treatment blood test
WBC as 109/L	7.37 ± 0.21	11.00 ± 0.61	0.000
BUN in mmol/L	6.89 ± 0.21	6.92 ± 0.75	0.974
Creatinine in µmol/L	86.82 ± 2.78	74.85 ± 7.46	0.227
CRP in mg/L	7.68 ± 0.54	18.97 ± 3.841	0.000
IL-6 in pg/mL	8.28 ± 0.68	18.76 ± 4.241	0.000
Procalcitonin in ng/mL	0.04 ± 0.01	0.09 ± 0.01	0.000
Duration of drainage in d	79 ± 3	104 ± 13	0.025
Catheter length in cm	7.13 ± 0.26	10.68 ± 0.66	0.000

¹Abnormally higher than normal range. Quantitative data are presented as the mean ± standard error of the mean. IPN: Infectious pancreatic necrosis; BISAP: Bedside index for severity in acute pancreatitis; APACHE II: Chronic Health Evaluation II; SIRS: Systemic inflammatory response syndrome; WBC: White blood cell; BUN: Blood urea nitrogen; CRP: C-reactive protein.